SC
VRTX icon

SRB Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

SRB Corp’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,476
Closed -$601K – 103
2023
Q4 		$601K Buy
1,476
+162
+12% +$59.8K 0.04% 22
2023
Q3 		$457K Hold
1,314
– – 0.03% 61
2023
Q2 		$462K Buy
1,314
+79
+6% +$26.6K 0.03% 43
2023
Q1 		$389K Sell
1,235
-234
-16% -$70.2K 0.02% 19
2022
Q4 		$424K Buy
1,469
+47
+3% +$14.3K 0.03% 83
2022
Q3 		$412K Buy
+1,422
New +$409K 0.03% 29
2021
Q1 		– Sell
-3,474
Closed -$821K – 165
2020
Q4 		$821K Buy
+3,474
New +$797K 0.06% 56
2019
Q4 		– Sell
-2,443
Closed -$414K – 169
2019
Q3 		$414K Sell
2,443
-326
-12% -$57.7K 0.04% 156
2019
Q2 		$508K Buy
+2,769
New +$484K 0.05% 69

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

SRB Corp's VRTX Position: Q1 2024 in Review

SRB Corp sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 1,476 shares — an estimated $601K sold.

SRB Corp first reported a position in VRTX in Q2 2019 and held it in 9 quarters. The position peaked at $821K in Q4 2020. 1,496 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • SRB Corp reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • SRB Corp sold 1,476 Vertex Pharmaceuticals shares in Q1 2024, an estimated $601K.
  • SRB Corp first reported a position in Vertex Pharmaceuticals in Q2 2019 and held it in 9 quarters.
  • SRB Corp's Vertex Pharmaceuticals position peaked at $821K in Q4 2020.
  • 1,496 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on SRB Corp's 13F filing for Q1 2024, filed 14 May 2024.